Andrew Owen
The CELT pharmacology group bring to bear cutting-edge preclinical expertise to a diverse portfolio of projects. The team work closely with local, national, and international partners to better understand mechanisms that underpin clinical phenotypes and to translate new interventions through the preclinical and clinical challenges. The teams’ expertise spans in vitro, in vivo, bioanalytical and pharmacokinetic modelling capability that is harmonised to achieve maximum value for their projects.
Steve Rannard
Steve is a Professor of Chemistry at the University of Liverpool, UK. He is a co-director of Centre of Excellence for Long-acting Therapeutics (CELT), the academic lead for Nanomedicine within the Materials Innovation Factory and Director of the Radiomaterials Laboratory within the Department of Chemistry. His therapeutic research primarily focuses advanced materials science onto unmet medical/clinical needs to target new patient benefits using scalable polymer syntheses, nanoparticle synthesis, solid drug nanoparticle formulation and nanoemulsion platforms. Steve spent 16 years in industry (Cookson, Courtaulds, Unilever) and has co-founded four start-up companies (IOTA NanoSolutions Ltd, Hydra Polymers Ltd, Tandem Nano Ltd and Polymer Mimetics Ltd). Steve was the first recipient of the RSC/Macro Group UK Young Researcher of the Year Medal, sequential RSC Industrial Lectureships at Strathclyde and Sussex, a visiting Lectureship at Sussex, visiting Professorship at UoL and a Royal Society Industry Fellowship.
Helen Cauldbeck
The Cauldbeck Group is a team of interdisciplinary scientists focused on the use of radiochemistry to provide deeper insights into the fields of nanomedicine, polymer chemistry, formulation and biomaterials science.
Marco Giardiello
The research aims of the Giardiello group are to develop novel Inorganic/Organic Nanocomposite Particles (I/O-NP) for use in both diagnostic and therapeutic nanomedicine, as well the development of hybrid nanoparticle structures that combine both therapeutic and diagnostic components, known as theranostics. Current research programmes are aimed at several emerging healthcare applications, including Proton Beam Therapy (PBT), Magnetic Particle Imaging (MPI), Optical Imaging and Magnetic Resonance Imaging (MRI) with a focus towards strategies for image guided therapy, targeted delivery and drug release monitoring.
Saye Khoo
The Infection Pharmacology group, led by Professor Saye Khoo, investigates drug interactions and develops clinical trials for CELT. The group works intensively in the Liverpool Bioanalytical Facility.
Neill Liptrott
Led by Dr Neill Liptrott, the Immunocompatibility Group aims to understand the concepts and mechanisms which underlay the interface of advanced materials and complex medicines with the immune system; to support their translation to clinical use and gain insight into the fundamental biology behind them. To date, we have worked with a wide variety of nanotherapeutics from lipidic nanoparticles to polymeric and from virosomes to exosomes for the delivery of diagnostics, small molecules, biopharmaceuticals, biopolymers and nucleic acids.
Adeniyi Olagunju
The perinatal period represents a critical developmental window during which the health and wellbeing of future generations is laid down. Led by Dr Adeniyi Olagunju, research within the Perinatal Pharmacology Group is focused on broadening our understanding of drug safety and efficacy during pregnancy and lactation. Working across three domains (human-relevant in vitro modelling, in silico modelling and clinical research), our goal is to generate actionable knowledge that will facilitate early recommendations for safe use of long-acting medicines during the perinatal period.
Tao You
Systems Medicine Group supports robust decision-making in drug discovery and development with advanced modelling of all accessible data. We aim to detect disease early, deliver the right drug to the right patients at the right dose, and find new cures to deadly diseases.
James Stewart
James Stewart holds the Chair of Molecular Virology at the University of Liverpool where he is also Head of the Department of Infection Biology and Microbiomes. He is an expert virologist with over 25 years experience in establishing and using mouse and small animal models of virus infection, molecular biology and immunology. The early part of his career was spent studying pathogenesis, with a particular focus on the herpesvirus family. he developed murine gammaherpesvirus in mice as a model for studying authentic host-virus interactions, exploiting the power of virus reverse genetics and KO mouse technology. More recently he has moved to focus on pathogens such as SARS-CoV-2. influenza A, respiratory syncytial virus and human rhinovirus. He has developed an integrative toolkit and pathway with which to do this. He uses conventional and molecular techniques to analyse the course of virus infection combined with big data techniques and informatics to relate the function of viral determinants with host defence responses. While still studying pathogenesis, the COVID epidemic has changed his focus, and a large part of his research is developing novel therapeutics and interventions for SARS-CoV-2 and other respiratory pathogens. He is currently leading small animal preclinical models of COVID-19 at the University of Liverpool. Prof Stewart has published over 120 peer-review manuscripts (h = 45). He leads and co-leads large multicentre research grants. Research funding has been secured from UK Biotechnology and Biological Sciences Research Council (BBSRC), the Medical Research Council (MRC), Innovate UK, UK Ministry of Defence, The Wellcome Trust, National Institutes for Health (NIH), and pharmaceutical companies. He has supervised >30 graduate students and mentored 20 PDRAs. He regularly sits on National and International funding award panels and is an academic editor for PLoS ONE. He is a member of the WHO COVID-19 animal models group. He Chairs the University Animal Welfare and Ethical Review Body.